國泰集團(603977.SH):擬對九江國泰增資用於投建含能新材料生產線項目
格隆匯5月8日丨國泰集團(603977.SH)公佈,公司擬通過全資子公司威源民爆以現金方式對其全資子公司九江國泰增資34,000萬元,用於建設年產3,000噸-4,300噸(多品種柔性)含能新材料生產線項目。增資完成後,九江國泰註冊資本由1,000萬元增至35,000萬元,仍為公司全資子公司威源民爆的下屬全資子公司。新建兩條含能新材料生產線,合計年產能3,000噸-4,300噸(多品種柔性);配套建設原料儲存、生產工房、理化分析、廢水處理、動力中心等建築物;項目配套的智能智造設備系統等。項目規模約12.38億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.